Keyphrases
Tumor Immunity
100%
Her2neu
100%
Anti-idiotypic Antibody
100%
Human Epidermal Growth Factor Receptor 2 (HER2)
36%
EL4 Cells
27%
Mouse Serum
18%
Tumor
9%
Antibody-based
9%
Overexpression
9%
Poor Prognosis
9%
Human Cancer
9%
Cancer Immunotherapy
9%
C57BL
9%
Immunization
9%
Epitope
9%
Oncogene
9%
Vaccine Approaches
9%
Flow Cytometric Analysis
9%
Therapeutic Vaccine
9%
Lethal Dose
9%
Flow Cytometry
9%
Suitable Target
9%
Antibody-dependent Cellular Cytotoxicity
9%
Keyhole Limpet Hemocyanin
9%
Multiple Persons
9%
SKBR3
9%
Murine Tumor Model
9%
Anti-idiotype
9%
Freund's Adjuvant
9%
Human Malignancies
9%
Human Breast Carcinoma Cells
9%
QS-21
9%
Immune Serum
9%
Medicine and Dentistry
Tumor Immunity
100%
Antiidiotypic Antibody
100%
Flow Cytometry
40%
Malignant Neoplasm
20%
Neoplasm
20%
Cancer
20%
Tumor Model
20%
Carcinoma Cell
20%
C57BL/6
20%
Proto Oncogene
20%
Cancer Immunotherapy
20%
Enzyme Linked Immunosorbent Assay
20%
Breast Carcinoma
20%
Antibody Dependent Cellular Cytotoxicity
20%
Tumor Vaccine
20%
Qs 21
20%
Antiserum
20%
Epitope
20%
Freund's Adjuvant
20%
Keyhole Limpet Hemocyanin
20%
Pharmacology, Toxicology and Pharmaceutical Science
Antiidiotypic Antibody
100%
Neoplasm
100%
Flow Cytometry
40%
Malignant Neoplasm
40%
Enzyme-Linked Immunosorbent Assay
20%
C57BL 6 Mouse
20%
Tumor Model
20%
Breast Carcinoma
20%
Tumor Vaccine
20%
QS21
20%
Immunotherapy
20%
Antiserum
20%
Keyhole Limpet Hemocyanin
20%
Epitope
20%
Freund's Adjuvant
20%
Cytotoxicity
20%
Immunology and Microbiology
Tumor Immunity
100%
Antiidiotypic Antibody
100%
Antiserum
20%
Freund's Adjuvant
20%
Carcinoma Cell
20%
ELISA
20%
Epitope
20%
Tumor Vaccine
20%
Proto Oncogene
20%
C57BL 6 Mouse
20%
Antibody-Dependent Cell-Mediated Cytotoxicity
20%
QS21
20%
Cancer Immunotherapy
20%
Keyhole Limpet Hemocyanin
20%